Document Detail


Effects of short-term propylthiouracil treatment on p wave duration and p wave dispersion in patients with overt hypertyroidism.
MedLine Citation:
PMID:  17701883     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: P-wave duration is defined as the time measured from the onset to the offset of the P-wave in surface electrocardiogram (ECG). Prolonged P wave duration and increased P wave dispersion (PWD) have been reported to carry an increased risk for atrial fibrillation. AIM: Our aim was to evaluate the role of hyperthyroidism on P wave duration and dispersion, to investigate the effect of anti-thyroid therapy on P wave duration and dispersion. MATERIAL AND METHODS: A total of 44 consecutive subjects (22 patients with newly diagnosed overt hyperthyroidism and 22 randomly selected euthyroid healthy subjects) were enrolled in the study. Transthoracic echocardiography, 12 lead surface ECG and thyroid hormone levels were studied at the time of enrollment, in the first and third months of the 6-8 mg/kg/day propylthiouracil therapy. Patients were followed-up for 3 months. RESULTS: Patient and control groups were consisted of age and sex matched subjects. Baseline left atrial diameter was similar between the patient and control groups (3.4+/-0.3 cm and 3.4+/-0.3 cm respectively, p=0.813). The maximum P-wave duration (P maximum) was 113.1+/-6.6 and 105.7+/-4.1 ms in patient and control groups (p=0.001). PWD was 31.5+/-9.5 and 25.2+/-5.9 ms in patient and control groups respectively (p=0.015). At the third month of propylthiouracil treatment P maximum and PWD were decreased in the patient group at statistically significant level and returned back in normal limits (p<0.001 and p=0.001). CONCLUSION: P wave duration and PWD are found prolonged in hyperthyroid patients and propylthiouracil treatment decreased them effectively. This mechanism may establish how the anti-thyroid treatment may prevent the development of atrial fibrillation in hyperthyroid patients.
Authors:
M T Katircibasi; F Deniz; B Pamukcu; S Binici; I Atar
Related Documents :
7797753 - Chiari's network: normal anatomic variant or risk factor for arterial embolic events?
18489943 - Prevalence and characterization of pulmonary vein variants in patients with atrial fibr...
18607903 - Audiologic abnormalities of fanconi anaemia.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association     Volume:  115     ISSN:  0947-7349     ISO Abbreviation:  Exp. Clin. Endocrinol. Diabetes     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-10-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505926     Medline TA:  Exp Clin Endocrinol Diabetes     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  376-9     Citation Subset:  IM    
Affiliation:
Etimesgut Military Hospital, Department of Cardiology, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antithyroid Agents / administration & dosage
Atrial Fibrillation / blood,  etiology,  physiopathology*,  prevention & control
Electrocardiography*
Female
Follow-Up Studies
Graves Disease / blood,  complications,  drug therapy,  physiopathology*
Humans
Male
Middle Aged
Propylthiouracil / administration & dosage
Thyroid Hormones / blood
Chemical
Reg. No./Substance:
0/Antithyroid Agents; 0/Thyroid Hormones; 51-52-5/Propylthiouracil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with...
Next Document:  Influence of body mass index on measured and calculated androgen parameters in adult women with Hirs...